Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol

NCT Number	NCT07152041
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Enrollment	150 participants
Start Date	2025-03-28
Primary Completion	2029-12 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-03